Single mutations or patterns of mutations in HIV can produce resistance to several different anti-HIV drugs. This means that once resistance to one drug has emerged, this HIV may also be resistant to drugs you haven't taken yet. This is called cross-resistance.

Cross-resistance may affect all currently available anti-HIV drugs to a greater or lesser extent. So resistance to one nucleoside analogue (NRTI) will affect your choice of other nucleoside analogues, resistance to a non-nucleoside analogue (NNRTI) drug will affect your choice of other NNRTIs, and resistance to a protease inhibitor will affect your choice of other protease inhibitors. Resistance to fusion, entry and integrase inhibitors may have implications for your choice of drugs from these classes in the future. 

New anti-HIV drugs are in development, but these too may well be affected by cross-resistance.